24 May 2013
Keywords: british, biotech, oral, mmpi, clears, phase, trials
Article | 27 March 1995
British Biotech's oral matrix metalloproteinase inhibitor for the
treatment of cancer, BB-2516, has successfully navigated Phase I studies
in healthy ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 March 1995
© 2013 thepharmaletter.com